By Section 409i of BPCA requires NIH and FDA to prioritize therapeutic areas in critical need of pediatric research. NICHD then facilitates clinical trials and data are submitted to FDA who determines if labeling changes are appropriate. This site lists such approved labeling changes.
Top News
- Pain and Arthritis Products Containing Hidden Ingredients
- Painflex Forte may be harmful due to hidden drug ingredients
- Max Chemical Inc. – 682037 – 06/20/2024
- Cholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals – 684036 – 07/09/2024
- YangZhou SuXiang Medical Instrument Co., Ltd. – 686655 – 07/08/2024
- Optikem International Inc. – 680264 – 06/20/2024
- 6 Things to Do in Ennis, Texas—From Bluebonnet Trails to a Railroad Museum
- ATM Glitch is Causing Chase to Sue Over 1,000 People—Were You Part of It?
- She Rescued a Dog on a Mountain—And He Rescued Her Family, Too
- April 21 to April 27 Horoscope Forecast: Your Zodiac Sign’s Week
- More Money Found: 11 Refunds and Credits You Can Get on Common Expenses
- 8-Year-Old Makes Easter Baskets for Hundreds of Kids in Need!
- China jumpstarts humanoid robot production with EV sector support
- Taiwan taps private sector for unmanned naval defense push
- CATL to mass-produce first sodium-ion battery by year-end
- Foxconn unveils AI-integrated EV, marking major push into global auto market
- Tesla’s 2025 slowdown reveals limits of the Musk playbook
- Taiwan rides AI wave as US tech orders surge
